2019 Clinic Individual Management 
The Clinical Problem Solvers
DECEMBER 16, 2020
Nwamaka Eneanya and Jennifer Tsai to discuss the limitations and harms of race-based medicine in clinical practice. Our guests explain how we can incorporate race-conscious medicine in clinical settings, medical education, and biomedical/epidemiological research to responsibly recognize and address the harms of racial inequality.
The Clinical Problem Solvers
APRIL 3, 2023
The dehumanization of individuals of color at the margins of society by the healthcare system is not simply a thing of the past, and is certainly a persistent phenomenon. Cindy Gladue, Brian Sinclair, and Joyce Echaquan are three Indigenous individuals who suffered immense harm at the hands of the healthcare system.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law Blog
OCTOBER 10, 2022
Javitt — On September 28, 2022, the FDA issued the long anticipated final Clinical Decision Support Software Guidance (CDS Guidance), which replaces the revised draft guidance document from 2019. Medical information about a patient. Other medical information.
FDA Law Blog
JANUARY 6, 2022
In general, EKRA prohibits, knowingly and willfully, soliciting, receiving, paying or offering kickbacks in exchange for referring to, inducing a referral to, or using the services of a recovery home, clinical treatment facility, or laboratory. 18 U.S.C. § 18 U.S.C. § 220(e)(2). 18 U.S.C. § 24(b) (emphasis added). 18 U.S.C. § 220(b)(2).
FDA Law Blog
MAY 8, 2023
In addition, manufacturers should identify whether the modifications will apply to all devices in the field (referred to as global adaptations) or will be implemented based on a specific clinical site or individual patients” (referred to as local adaptations).
FDA Law Blog
JANUARY 6, 2022
In general, EKRA prohibits, knowingly and willfully, soliciting, receiving, paying or offering kickbacks in exchange for referring to, inducing a referral to, or using the services of a recovery home, clinical treatment facility, or laboratory. 18 U.S.C. § 18 U.S.C. § 220(e)(2). 18 U.S.C. § 24(b) (emphasis added). 18 U.S.C. § 220(b)(2).
Physician's Weekly
JUNE 21, 2025
Variceal glue therapy with non-selective β blockers (NSBB) is a standard approach for managing acute fundal variceal bleeding and reducing rebleeding risk in individuals with cirrhosis. The primary composite outcome was all-cause mortality or clinically significant rebleeding within 1 year. 0.51]; P <0.0001).
Expert insights. Personalized for you.
52 
Let's personalize your content